Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3854568 | 0.88 | ALDH1A1 (0.48) | MAPK1SMN1; SMN2PDE4APDE4BPDE4C | |
| SCHEMBL3851359 | 0.84 | MAPK1 (0.54) | MAPK1SMN1; SMN2POLBPDE4APDE4B | |
| SCHEMBL3851331 | 0.84 | EGLN3 (0.58) | MAPK1SMN1; SMN2POLBPDE4APDE4B | |
| SCHEMBL3849121 | 0.83 | MAPK1 (0.48) | MAPK1SMN1; SMN2POLBPDE4APDE4B | |
| SCHEMBL3856401 | 0.83 | ALDH1A1 (0.53) | MAPK1SMN1; SMN2PDE4BKDM4ETDP1 | |
| SCHEMBL3852981 | 0.83 | KDM4E (0.48) | MAPK1SMN1; SMN2KDM4ETDP1RECQL | |
| SCHEMBL3847510 | 0.82 | EGLN3 (0.55) | MAPK1SMN1; SMN2POLBPDE4APDE4B | |
| SCHEMBL3850103 | 0.82 | PDE4A (0.52) | MAPK1SMN1; SMN2POLBPDE4APDE4B | |
| SCHEMBL3851363 | 0.81 | PDE4A (0.61) | MAPK1SMN1; SMN2POLBPDE4APDE4B | |
| SCHEMBL3857672 | 0.81 | KDM4E (0.47) | MAPK1SMN1; SMN2PDE4DKDM4ERECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2889289-A1 | Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors | GlaxoSmithKline LLC (US) | 2015-07-01 | — | — | EP | disclosed |
| US-RE44613-E1 | N-substituted glycine derivatives: hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-26 | — | — | US | disclosed |
| US-7608621-B2 | Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production | SMITHKLINE BEECHAM, CORP. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080214549-A1 | N-Substituted Glycine Derivatives: Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214549-A1 | N-Substituted Glycine Derivatives: Hydroxylase Inhibitors | EGLN2, EGLN3, HIF1AN | MAPK1 2489/4885SMN1; SMN2 3490/4885POLB 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.